Login Register Cart 0
Review Article

药物治疗对IBD手术策略的影响

卷 20, 期 13, 2019

页: [1363 - 1368] 页: 6

弟呕挨: 10.2174/1389450120666190515095520

价格: $65

摘要

尽管改变了医学模式，但仍有很大一部分IBD患者需要手术。 病人的总体状况，包括营养状况和使用免疫抑制药物，对于手术并发症以及最佳手术策略的选择非常重要。 手术的适应症和手术时机是IBD患者多学科治疗的关键因素。 本文的目的是概述药物治疗对IBD手术策略的影响。

关键词: 抗TNF，结肠切除术，（复杂的）克罗恩病，免疫抑制剂，多学科溃疡性结肠炎。

« Previous Next »
[1]
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110(9): 1324-38.
[http://dx.doi.org/10.1038/ajg.2015.233] [PMID: 26303131]
[2]
Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis 2017; 11(1): 3-25.
[http://dx.doi.org/10.1093/ecco-jcc/jjw168] [PMID: 27660341]
[3]
Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management. J Crohn’s Colitis 2017; 11(7): 769-84.
[http://dx.doi.org/10.1093/ecco-jcc/jjx009] [PMID: 28513805]
[4]
Sandborn WJ, Su C, Sands BE, et al. tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376(18): 1723-36.
[http://dx.doi.org/10.1056/NEJMoa1606910] [PMID: 28467869]
[5]
Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: A nationwide cohort study 1979-2011. Gut 2014; 63(10): 1607-16.
[http://dx.doi.org/10.1136/gutjnl-2013-305607] [PMID: 24056767]
[6]
Sahami S, Bartels SA, D’Hoore A, et al. A Multicentre evaluation of risk factors for anastomotic leakage after restorative proctocolectomy with ileal pouch-anal anastomosis for inflammatory bowel disease. J Crohn’s Colitis 2016; 10(7): 773-8.
[http://dx.doi.org/10.1093/ecco-jcc/jjv170] [PMID: 26417046]
[7]
Sahami S, Buskens CJ, Fadok TY, et al. Defunctioning ileostomy is not associated with reduced leakage in proctocolectomy and ileal pouch anastomosis surgeries for IBD. J Crohn’s Colitis 2016; 10(7): 779-85.
[http://dx.doi.org/10.1093/ecco-jcc/jjv201] [PMID: 26512136]
[8]
Gu J, Stocchi L, Remzi F, Kiran RP. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Colorectal Dis 2013; 15(9): 1123-9.
[http://dx.doi.org/10.1111/codi.12267] [PMID: 23627886]
[9]
Markel TA, Lou DC, Pfefferkorn M, et al. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis. Surgery 2008; 144(4): 540-5.
[http://dx.doi.org/10.1016/j.surg.2008.07.005] [PMID: 18847637]
[10]
Øresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn’s Colitis 2015; 9(1): 4-25.
[http://dx.doi.org/10.1016/j.crohns.2014.08.012] [PMID: 25304060]
[11]
Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125(2): 320-7.
[http://dx.doi.org/10.1016/S0016-5085(03)00883-7] [PMID: 12891531]
[12]
Miki C, Ohmori Y, Yoshiyama S, et al. Factors predicting postoperative infectious complications and early induction of inflammatory mediators in ulcerative colitis patients. World J Surg 2007; 31(3): 522-9.
[http://dx.doi.org/10.1007/s00268-006-0131-4] [PMID: 17334865]
[13]
Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15(7): 1062-70.
[http://dx.doi.org/10.1002/ibd.20863] [PMID: 19161179]
[14]
Mahadevan U, Loftus EV Jr, Tremaine WJ, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8(5): 311-6.
[http://dx.doi.org/10.1097/00054725-200209000-00001] [PMID: 12479645]
[15]
Zmora O, Khaikin M, Pishori T, et al. Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives? Int J Colorectal Dis 2007; 22(3): 289-92.
[http://dx.doi.org/10.1007/s00384-006-0168-8] [PMID: 16932926]
[16]
Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J Pediatr Surg 2007; 42(1): 31-4.
[http://dx.doi.org/10.1016/j.jpedsurg.2006.09.006] [PMID: 17208537]
[17]
Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006; 93(7): 793-9.
[http://dx.doi.org/10.1002/bjs.5375] [PMID: 16710880]
[18]
Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204(5): 956-62.
[http://dx.doi.org/10.1016/j.jamcollsurg.2006.12.044] [PMID: 17481518]
[19]
Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51(8): 1202-7.
[http://dx.doi.org/10.1007/s10350-008-9364-7] [PMID: 18536964]
[20]
Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. Aliment Pharmacol Ther 2012; 35(11): 1301-9.
[http://dx.doi.org/10.1111/j.1365-2036.2012.05099.x] [PMID: 22506582]
[21]
Eshuis EJ, Al Saady RL, Stokkers PC, Ponsioen CY, Tanis PJ, Bemelman WA. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohn’s Colitis 2013; 7(2): 142-9.
[http://dx.doi.org/10.1016/j.crohns.2012.03.013] [PMID: 22542056]
[22]
Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36(10): 922-8.
[http://dx.doi.org/10.1111/apt.12060] [PMID: 23002804]
[23]
Yung DE, Horesh N, Lightner AL, et al. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. Inflamm Bowel Dis 2018; 24(11): 2327-38.
[http://dx.doi.org/10.1093/ibd/izy156] [PMID: 29788385]
[24]
Gardenbroek TJ, Musters GD, Buskens CJ, et al. Early reconstruction of the leaking ileal pouch-anal anastomosis: a novel solution to an old problem. Colorectal Dis 2015; 17(5): 426-32.
[http://dx.doi.org/10.1111/codi.12867] [PMID: 25512241]
[25]
Rottoli M, Di Simone MP, Vallicelli C, et al. Endoluminal vacuum-assisted therapy as treatment for anastomotic leak after ileal pouch-anal anastomosis: a pilot study. Tech Coloproctol 2018; 22(3): 223-9.
[http://dx.doi.org/10.1007/s10151-018-1762-9] [PMID: 29502228]
[26]
Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002; 8(4): 244-50.
[http://dx.doi.org/10.1097/00054725-200207000-00002] [PMID: 12131607]
[27]
Kumar RR, Kim JT, Haukoos JS, et al. Factors affecting the successful management of intra-abdominal abscesses with antibiotics and the need for percutaneous drainage. Dis Colon Rectum 2006; 49(2): 183-9.
[http://dx.doi.org/10.1007/s10350-005-0274-7] [PMID: 16322960]
[28]
Bermejo F, Garrido E, Chaparro M, et al. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn’s disease: are antibiotics enough? Inflamm Bowel Dis 2012; 18(8): 1509-14.
[http://dx.doi.org/10.1002/ibd.21865] [PMID: 22674826]
[29]
Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn’s disease. Clin Gastroenterol Hepatol 2011; 9(10): 842-50.
[http://dx.doi.org/10.1016/j.cgh.2011.04.023] [PMID: 21679776]
[30]
Golfieri R, Cappelli A. Computed tomography-guided percutaneous abscess drainage in coloproctology: Review of the literature. Tech Coloproctol 2007; 11(3): 197-208.
[http://dx.doi.org/10.1007/s10151-007-0354-x] [PMID: 17676271]
[31]
Sahai A, Bélair M, Gianfelice D, et al. Percutaneous drainage of intra-abdominal abscesses in Crohn’s disease: short and long-term outcome. Am J Gastroenterol 1997; 92(2): 275-8.
[PMID: 9040205]
[32]
da Luz Moreira A, Stocchi L, Tan E, Tekkis PP, Fazio VW. Outcomes of Crohn’s disease presenting with abdominopelvic abscess. Dis Colon Rectum 2009; 52(5): 906-12.
[http://dx.doi.org/10.1007/DCR.0b013e31819f27c3] [PMID: 19502855]
[33]
Nguyen DL, Sandborn WJ, Loftus EV Jr, et al. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2012; 10(4): 400-4.
[http://dx.doi.org/10.1016/j.cgh.2011.11.023] [PMID: 22155562]
[34]
He X, Lin X, Lian L, et al. Preoperative percutaneous drainage of spontaneous intra-abdominal abscess in patients with Crohn’s Disease: A meta-analysis. J Clin Gastroenterol 2015; 49(9): e82-90.
[http://dx.doi.org/10.1097/MCG.0000000000000219] [PMID: 25216386]
[35]
Patil SA, Cross RK. Medical versus surgical management of penetrating Crohn’s disease: the current situation and future perspectives. Expert Rev Gastroenterol Hepatol 2017; 11(9): 843-8.
[http://dx.doi.org/10.1080/17474124.2017.1342536] [PMID: 28633544]
[36]
Kim DH, Cheon JH, Moon CM, et al. Clinical efficacy of nonsurgical treatment of Crohn’s disease-related intraabdominal abscess. Korean J Gastroenterol 2009; 53(1): 29-35.
[PMID: 19158468]
[37]
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340(18): 1398-405.
[http://dx.doi.org/10.1056/NEJM199905063401804] [PMID: 10228190]
[38]
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350(9): 876-85.
[http://dx.doi.org/10.1056/NEJMoa030815] [PMID: 14985485]
[39]
Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn’s disease. Am J Gastroenterol 2004; 99(3): 445-9.
[http://dx.doi.org/10.1111/j.1572-0241.2004.04083.x] [PMID: 15056083]
[40]
Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010; 139(4): 1147-55.
[http://dx.doi.org/10.1053/j.gastro.2010.06.070] [PMID: 20637205]
[41]
Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012; 55(11): 1138-44.
[http://dx.doi.org/10.1097/DCR.0b013e3182698f60] [PMID: 23044674]
[42]
Gross ME, Vogler SA, Mone MC, Sheng X, Sklow B. The importance of extended postoperative venous thromboembolism prophylaxis in IBD: A national surgical quality improvement program analysis. Dis Colon Rectum 2014; 57(4): 482-9.
[http://dx.doi.org/10.1097/DCR.0000000000000090] [PMID: 24608305]
[43]
Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008; 103(9): 2373-81.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01942.x] [PMID: 18616660]
[44]
Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn’s disease. Aliment Pharmacol Ther 2014; 40(9): 1009-22.
[http://dx.doi.org/10.1111/apt.12947] [PMID: 25209947]

Rights & Permissions Print Cite
Article Metrics
38
3
© 2024 Bentham Science Publishers | Privacy Policy